Evaluating circulating immunologic markers in the development of multiple myeloma
To accomplish this, we are requesting data on selected demographic and other characteristics of all participants from the screening arm of PLCO, including those with MGUS and MM included in our EEMS study. These data will be used to assign sampling weights for weighted Cox regression models to predict the likelihood of progression from MGUS to MM. We will assess improvements in risk prediction for individual markers as well as a composite marker score based on multiple logistic regression and validated with 5-fold cross-validation (Harrell, 2001) as was previously done to develop an inflammation score that predicts lung cancer risk (Shiels et al, 2015).
1. To evaluate whether incorporating selected immunologic markers into existing risk stratification models can improve our ability to identify MGUS-positive subjects at high risk of progression to clinically manifest MM.
Mark Purdue
Hormuzd Katki
Ola Landgren
-
Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Chang VC, Khan AA, Huang WY, Katki HA, Purdue MP, Landgren O, Hofmann JN
Blood Cancer J. 2022 Apr 1; Volume 12 (Issue 4): Pages 51 PUBMED